DT-120, an optimized LSD formulation, shows lasting anxiety relief and high remission at 12 weeks, as researchers share detailed phase 2b safety insights.
Jessica Malberg, PhD
Advertisement
Articles by Jessica Malberg, PhD
Phase 2b data show DT‑120, optimized oral LSD, delivers durable GAD remission with mostly same‑day side effects; phase 3 trials advance.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
Sex Differences, Sleep Problems, and Psychological Well-Being in Older Adults
2
Treating Patients With First-Episode Psychosis: Lessons From McLean OnTrack
3
Zolpidem: Restoring Sleep and Slowing Alzheimer Disease Progression
4
Sleep, Cognition, and the Bidirectional Brain, With Michael Scullin, PhD
5